Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Minority Interest (2022 - 2025)

Biote has reported Minority Interest over the past 4 years, most recently at $8.1 million for Q4 2025.

  • Quarterly results put Minority Interest at $8.1 million for Q4 2025, up 118.4% from a year ago — trailing twelve months through Dec 2025 was $8.1 million (up 118.4% YoY), and the annual figure for FY2025 was $8.1 million, up 118.4%.
  • Minority Interest for Q4 2025 was $8.1 million at Biote, up from $7.3 million in the prior quarter.
  • Over the last five years, Minority Interest for BTMD hit a ceiling of $8.1 million in Q4 2025 and a floor of -$35.3 million in Q1 2023.
  • Median Minority Interest over the past 4 years was -$7.1 million (2023), compared with a mean of -$7.4 million.
  • Biggest five-year swings in Minority Interest: dropped 21.04% in 2023 and later soared 270.65% in 2025.
  • Biote's Minority Interest stood at -$13.8 million in 2022, then soared by 48.25% to -$7.1 million in 2023, then skyrocketed by 152.15% to $3.7 million in 2024, then soared by 118.4% to $8.1 million in 2025.
  • The last three reported values for Minority Interest were $8.1 million (Q4 2025), $7.3 million (Q3 2025), and $6.3 million (Q2 2025) per Business Quant data.